AquaBounty Facing Environmental Complaint in Panama
By admin,
The Guardian
| 11. 23. 2013
A U.S. company with a Prince Edward Island research facility is facing a complaint in Panama alleging that it is in breach of the country’s environmental regulations.
The Environmental Advocacy Center of Panama submitted a complaint to the country’s National Environmental Authority earlier this week alleging that AquaBounty’s research and development of Genetically Modified (GM) Atlantic salmon is in breach of environmental regulations.
The company produces salmon eggs in P.E.I., which are then shipped to Panama for further research and development.
Sharon Labchuk, of the P.E.I. group “Islanders Say No to Frankenfish”, said she was surprised at the complaint.
“We always assume that because something is as controversial as this is, the proper controls are in place,” said Labchuk. “It’s also very experimental and the risks of anything going wrong are disastrous. They can wipe out the wild salmon population if these fish ever escape and their eggs end up in the wild rivers.”
The National Environmental Authority in Panama conducted an inspection of the AquaBounty operation in 2012 and allegedly found violations that remained uncorrected by the company. Those...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...